Athenex, Inc.
(NASDAQ : ATNX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.60%162.580.7%$1033.26m
MRKMerck & Co., Inc. -0.67%76.710.7%$980.93m
LLYEli Lilly & Co. -1.09%219.801.1%$902.43m
PFEPfizer Inc. -1.51%38.890.9%$887.72m
ABBVAbbVie, Inc. -1.44%113.251.9%$722.70m
BMYBristol-Myers Squibb Co. -0.63%66.351.0%$618.54m
AZNAstraZeneca Plc -1.00%57.771.2%$393.63m
ANVSAnnovis Bio, Inc. 4.64%94.230.0%$320.63m
OGN -3.61%30.330.0%$316.44m
NVSNovartis AG -1.12%93.100.2%$179.83m
GSKGlaxoSmithKline Plc -1.91%39.800.2%$149.33m
NOVNNovan, Inc. 0.46%10.905.8%$140.53m
ORPHOrphazyme A/S -47.80%7.600.0%$123.41m
BTXBrooklyn ImmunoTherapeutics, Inc. 10.20%16.9112.4%$104.70m
CNSTConstellation Pharmaceuticals, Inc. -0.18%33.760.0%$104.65m

Company Profile

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.